journal article·2025-04-23

Epigenetically Reprogrammed Nanovesicles as Inverse Vaccines for Antigen-Specific Immune Tolerance in Autoimmune Diseases

Yue Xi, Huifeng Ma, Xue Liu, Qianwen Mu, Xiaoyu An, Shuo Li, Hao Liang, Di Sun, Rongrong Ma, Haolan Deng, Zhengyu Wu, Chenhao Zhang, Gang Liu, Chao Liu

Nano Letters· Volume 25· Issue 16
Publisher page

Abstract

The development of antigen-specific immunotherapy for autoimmune diseases constitutes an important unmet clinical need. Here we present an innovative inverse vaccine platform leveraging epigenetic reprogramming to induce durable antigen-specific immune tolerance. This inverse vaccine (mDCNVreg) is constructed using artificial cell membrane nanovesicles derived from IFN-γ-primed regulatory dendritic cells subjected to epigenetic modulation. The engineered mDCNVreg features upregulated MHC-II expression enabling targeted antigen presentation, suppressed costimulatory molecules expression, and an enhanced coinhibitory molecules display. Through coordinated mechanisms involving enhanced lymphoid trafficking and phenotype stabilization, this platform significantly enhances antigen delivery to secondary lymphoid organs while maintaining tolerogenic potency. Crucially, mDCNVreg directly induces CD4+ T cell clonal anergy through epitope-specific interactions, establishing long-lasting immune tolerance. This work demonstrates a promising epigenetic engineering approach for reverse vaccine design in personalized autoimmune disease therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · vaccines and immunoinformatics approaches · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences

Xiamen University

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health

State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Biology, School of Life Sciences

Shenzhen Research Institute of Xiamen University

Funding

Basic and Applied Basic Research Foundation of Guangdong Province · Science, Technology and Innovation Commission of Shenzhen Municipality · Major State Basic Research Development Program of China · National Natural Science Foundation of China

References (62)

Show source-provided references
1. 10.1126/science.adg748910.1126/science.adg7489 ↗
2. 10.1038/s41584-022-00849-610.1038/s41584-022-00849-6 ↗
3. 10.1038/467502d10.1038/467502d ↗
4. 10.1586/eri.10.17810.1586/eri.10.178 ↗
5. 10.1038/nature1730010.1038/nature17300 ↗
6. 10.1038/nri215310.1038/nri2153 ↗
7. 10.3389/fimmu.2019.0126510.3389/fimmu.2019.01265 ↗
8. 10.1038/s41467-024-45170-w10.1038/s41467-024-45170-w ↗
9. 10.1016/j.immuni.2023.01.00410.1016/j.immuni.2023.01.004 ↗
10. 10.1016/j.immuni.2019.01.02010.1016/j.immuni.2019.01.020 ↗
11. 10.1016/j.jaci.2023.09.02510.1016/j.jaci.2023.09.025 ↗
12. 10.1016/j.cell.2022.10.02610.1016/j.cell.2022.10.026 ↗
13. 10.1016/S0140-6736(23)01126-110.1016/S0140-6736(23)01126-1 ↗
14. 10.1126/scitranslmed.ado208410.1126/scitranslmed.ado2084 ↗
15. 10.1016/j.tips.2024.07.00510.1016/j.tips.2024.07.005 ↗
16. 10.1038/s41591-022-02017-510.1038/s41591-022-02017-5 ↗
17. 10.1056/NEJMoa230891710.1056/NEJMoa2308917 ↗
18. 10.1038/s41584-024-01139-z10.1038/s41584-024-01139-z ↗
19. 10.1016/j.molmed.2018.08.00510.1016/j.molmed.2018.08.005 ↗
20. 10.1038/s41467-023-36594-x10.1038/s41467-023-36594-x ↗
21. 10.1016/j.it.2019.08.00310.1016/j.it.2019.08.003 ↗
22. 10.1038/s41423-021-00726-410.1038/s41423-021-00726-4 ↗
23. 10.1016/S1568-9972(03)00104-610.1016/S1568-9972(03)00104-6 ↗
24. 10.1016/j.addr.2017.04.00510.1016/j.addr.2017.04.005 ↗
25. 10.1038/s41565-020-00810-210.1038/s41565-020-00810-2 ↗
26. 10.1136/ard.2008.09917610.1136/ard.2008.099176 ↗
27. 10.1038/nature1696210.1038/nature16962 ↗
28. 10.1016/j.immuni.2011.09.01210.1016/j.immuni.2011.09.012 ↗
29. 10.1038/s41598-018-33248-710.1038/s41598-018-33248-7 ↗
30. 10.1136/annrheumdis-2015-20845610.1136/annrheumdis-2015-208456 ↗
31. 10.3389/fimmu.2020.59962310.3389/fimmu.2020.599623 ↗
32. 10.1016/j.jaci.2021.06.01210.1016/j.jaci.2021.06.012 ↗
33. 10.1016/j.celrep.2023.11219310.1016/j.celrep.2023.112193 ↗
34. 10.1016/j.annonc.2020.10.47810.1016/j.annonc.2020.10.478 ↗
35. 10.3389/fimmu.2022.93434310.3389/fimmu.2022.934343 ↗
36. 10.1016/j.autrev.2014.10.01010.1016/j.autrev.2014.10.010 ↗
37. 10.3389/fimmu.2018.0280410.3389/fimmu.2018.02804 ↗
38. 10.1093/intimm/dxh00310.1093/intimm/dxh003 ↗
39. 10.4049/jimmunol.110016810.4049/jimmunol.1100168 ↗
40. 10.1016/j.celrep.2022.11042010.1016/j.celrep.2022.110420 ↗
41. 10.1016/j.autrev.2023.10332810.1016/j.autrev.2023.103328 ↗
42. 10.1189/jlb.111258910.1189/jlb.1112589 ↗
43. 10.1189/jlb.030715310.1189/jlb.0307153 ↗
44. 10.1016/j.intimp.2021.10797810.1016/j.intimp.2021.107978 ↗
45. 10.1038/s41565-022-01098-010.1038/s41565-022-01098-0 ↗
46. 10.1002/adma.20180829410.1002/adma.201808294 ↗
47. 10.1002/advs.20210046010.1002/advs.202100460 ↗
48. 10.1002/anie.20231948910.1002/anie.202319489 ↗
49. 10.1002/advs.20210233010.1002/advs.202102330 ↗
50. 10.1002/adma.20230280110.1002/adma.202302801 ↗
51. 10.1002/adma.20210881710.1002/adma.202108817 ↗
52. 10.1002/adma.20220595010.1002/adma.202205950 ↗
53. 10.1038/nri213210.1038/nri2132 ↗
54. 10.1002/eji.20164661810.1002/eji.201646618 ↗
55. 10.1016/j.addr.2023.11508010.1016/j.addr.2023.115080 ↗
56. 10.1016/j.immuni.2019.03.02110.1016/j.immuni.2019.03.021 ↗
57. 10.1007/s00281-019-00741-810.1007/s00281-019-00741-8 ↗
58. 10.1016/j.immuni.2019.03.02210.1016/j.immuni.2019.03.022 ↗
59. 10.1038/s41586-020-1999-010.1038/s41586-020-1999-0 ↗
60. 10.1038/s41422-020-0324-710.1038/s41422-020-0324-7 ↗
61. 10.1146/annurev.immunol.19.1.68310.1146/annurev.immunol.19.1.683 ↗
62. 10.1016/j.immuni.2008.02.01710.1016/j.immuni.2008.02.017 ↗